Phuturdex › Diseases › Respiratory tract infection
Drugs in development · updated 30 October 2026
Respiratory tract infection: drugs in development
As of 30 October 2026 there are 17 active clinical trials (recruiting or ongoing, phases I–III) on 46 drugs for respiratory tract infection. 10 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Ibuzatrelvir | III | 2 | NCT06679140 |
| Broncho-Vaxom | III | 1 | NCT05063149 |
| DMX-200 | III | 1 | NCT02735707 |
| Eritoran | III | 1 | NCT02735707 |
| Rengalin | III | 1 | NCT07171099 |
| Tozorakimab | III | 1 | NCT05624450 |
| AV-001 | II | 1 | NCT05123755 |
| BEZ235RTB101 | II | 1 | NCT03373903 |
| JKN2501 | I | 1 | NCT07207291 |
| Ohio-99 | I | 1 | NCT07215871 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Baloxavir MarboxilXofluza® | III | 2 | NCT07827599 |
| MoxifloxacinIZILOX, Moxeza® | III | 2 | NCT06253715 |
| RemdesivirVeklury | III | 2 | NCT07013474 |
| Abrysvo | III | 1 | NCT07232706 |
| AnakinraKINERET | III | 1 | NCT02735707 |
| ApremilastOtezla, Apremilast Accord® | III | 1 | NCT02735707 |
| AspirinVazalore®, Durlaza® | III | 1 | NCT02735707 |
| Baloxavir | III | 1 | NCT07314905 |
| BaricitinibOlumiant® | III | 1 | NCT02735707 |
| Ceftaroline fosamilCeftaroline, Teflaro® | III | 1 | NCT02735707 |
| CeftriaxoneROCEPHIN, Ceftriaxone And Dextrose In Duplex Container® | III | 1 | NCT02735707 |
| CysteamineCystadrops®, Cystaran® | III | 1 | NCT02735707 |
| EthambutolMyambutol® | III | 1 | NCT06253715 |
| HydrocortisoneHydrocortison cream, Khindivi® | III | 1 | NCT02735707 |
| HydroxychloroquineSovuna®, Plaquenil® | III | 1 | NCT02735707 |
Sorted by most advanced phase and number of active trials. Showing 15 of 36 drugs.
All 46 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- COVID-19 104 drugs
- Influenza 68 drugs
- Post-Acute COVID-19 Syndrome 44 drugs
- Pulmonary tuberculosis 36 drugs
- Pneumonia 63 drugs
- Community-acquired pneumonia 45 drugs
- Tuberculosis 48 drugs
- Coronavirus disease 18 drugs
- Pharyngitis 5 drugs
- Chronic obstructive pulmonary disease 89 drugs
- Bacterial pneumonia 4 drugs
- Acute respiratory distress syndrome 43 drugs
Broader categories
- Respiratory disease 57 drugs
- Infection 71 drugs
- RNA virus infectious disease 8 drugs
- Virus Diseases 26 drugs
- Urogenital Diseases 16 drugs
- Lung disease 104 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D012141 “Respiratory Tract Infections”.